MyShare
Similar stories
headline news | recent news | latest news | market news | recent topics | stock topics
Global news - chevrons indicate local prediction, arrows show global predictions, circles show importance
Text search
| Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg). globenewswire - 42m ago - story - NTLA US | |
| Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc. AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ('Oncotelic', the 'Company' or 'We' or Our), announced today that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. (OTCPK: CPMV) (Mosaic) under which Mosaic will acquire rights to Oncotelics clinical-stage necroptosis cancer therapies. Oncotelics necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through death receptor activation which can result in a robust anti-cancer immune response. In addition to the clinical stage assets, Mosaic will have access to Oncotelics proprietary Artificial Intelligence (AI) technologies for identifying immunotherapy combinations. globenewswire - 1h ago - story - MOS US | |
| Ocugen Announces OCU400Modifier Gene TherapyPhase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN ), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of MedicinePhoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA. 'I look forward to sharing more about my clinical experience with this novel modifier gene therapy with my peers and industry leadership during the summit,' said Dr. Bakall. 'There remains a significant unmet need for patients with retinitis pigmentosa (RP) and I believe that this approach can offer a new therapeutic option to address the disease itself.' The Retinal Cell and Gene Therapy Innovation Summit 20 benzinga - 1h ago - story - | |
| Ocugen Announces OCU400Modifier Gene TherapyPhase 1/2 Data Presentation atRetinal Cell and Gene Therapy Innovation Summit 2024 MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of MedicinePhoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA. globenewswire - 1h ago - story - | |
| Which pharmaceutical companies have the most gas dosed drugs? This chart shows the pharmaceutical companies with the most gas dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most gas dosed drugs Source The post Which pharmaceutical companies have the most gas dosed drugs? appeared first on Biotechblog . biotechblog - 8h ago - story - | |
| Which pharmaceutical companies have the most spray dosed drugs? This chart shows the pharmaceutical companies with the most spray dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most spray dosed drugs Source The post Which pharmaceutical companies have the most spray dosed drugs? appeared first on Biotechblog . biotechblog - 04:09 Sun - story - | |
| Poorer English Breast Cancer Survivors Face Higher Second Cancer Risk A study of nearly 600,000 people also revealed younger patients were also at a higher risk of getting another cancer after having survived breast cancer. forbes - 18:18 Sun - story - | |
| ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that the U.S. Food and Drug Administration (FDA') has issued a safe to proceed' notice for its investigational new drug (IND') application for a Phase 1b study of its novel dry powder formulation of INNA-051. A virus-agnostic intranasal antiviral host defence immunomodulator, INNA-051 is a potent first-in-class agonist of toll-like receptor 2/6 (TLR2/6) which plays a key role in recognizing pathogens and triggering the innate immune response. Having demonstrated accelerated viral clearance and local stimulation of antiviral host defences in a Phase IIa proof-of-principle study using a liquid formulation in an influenza-challenge model, ENA Respiratory has developed an improved dry powder formulati benzinga - 4h ago - story - | |
| Breaking Cancer Barriers: ImmunityBios ANKTIVA Triumph ImmunityBio (IBRX) announced positive results from the QUILT 3.055 study evaluating ANKTIVA (N-803) in 2nd- and 3rd-line NSCLC patients who previously failed checkpoint inhibitor therapy. ANKTIVA, combined with checkpoint inhibitors, significantly prolonged overall survival in these patients, regardless of PD-L1 status. This outcome validates the drug's mechanism involving natural killer cells and T-cell memory, offering […] This article Breaking Cancer Barriers: ImmunityBio’s ANKTIVA Triumph appeared first on Guerilla Stock Trading . guerillastocktrading - 22:07 Sun - story - | |
| Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI STOCKHOLM, April 29, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide... prnewswire:443 - 3h ago - story - | |
| 5 Cheapest Countries to Study Abroad This article discusses the 5 Cheapest Countries to Study Abroad. If you want to get a detailed analysis of the global education sector, you can head on to 20 Cheapest Countries to Study Abroad. 5. Spain Average tuition fee: $1,805 With a literacy rate of 98.6%, Spain provides a special combination of rich cultural experiences […] insidermonkey - 9h ago - story - | |
| Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the 'Company' or 'Cognition') (NASDAQ: CGTX ), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that the company has reached target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER (COG1201) study ( NCT05225415 ), which is examining the safety and effectiveness of CT1812 in adults with mild-to-moderate dementia with Lewy bodies (DLB). Top-line results are expected inthe second half of 2024 after the last participants have completed six months of treatment. 'There are currently no approved disease-modifying therapies for DLB, leaving people living with this disease in desperate need of treatment options,' Lisa Ricciardi , president and CEO of Cognition Therapeutics, stated, 'The majority of patients with DLB have both A and -synuclein pathology. Because of our unique mechanism of action that targets both A and -synuclein oligomers, benzinga - 41m ago - story - | |
| All grown up, but still fighting? Why more siblings are turning to therapy, together Plenty of people go to couples therapy why not siblings therapy? Experts say the long, complicated relationships between siblings are worth exploring and tending to. npr org - 3h ago - story - | |
| MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease MANNKIND ANNOUNCES IND CLEARANCE FROM U.S. FDA TO START PHASE 3 STUDY OF CLOFAZIMINE INHALATION SUSPENSION FOR NTM LUNG DISEASE globenewswire - 2h ago - story - MNKD US | |
| CENTURY LITHIUM ANNOUNCES POSITIVE FEASIBILITY STUDY FOR THE CLAYTON VALLEY LITHIUM PROJECT, NEVADA FEASIBILITY STUDY HIGHLIGHTS Large-Scale Nevada-based Lithium Project: three-phase production plan will generate a life-of-mine average of 34,000 tonnes per annum (tpa) of battery-quality lithium carbonate (Li2CO3) Innovative Approach in Processing: patent-pending chloride leaching... prnewswire:443 - 2h ago - story - | |
| Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data highlighting the safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor, at the European Society of Clinical Microbiology & Infectious Diseases Global 2024 (ESCMID, formerly ECCMID), which is taking place April 27-30, 2024 in Barcelona, Spain. globenewswire - 1h ago - story - | |
| The Effects of Various Approaches to Lobectomies on Respiratory Muscle Strength, Diaphragm Thickness, and Exercise Capacity in Lung Cancer. The most common surgery for non-small cell lung cancer is lobectomy, which can be performed through either thoracotomy or video-assisted thoracic surgery (VATS). Insufficient research has examined respiratory muscle function and exercise capacity in lobectomy performed using conventional thoracotomy (CT), muscle-sparing thoracotomy (MST), or VATS. This study aimed to assess and compare respiratory muscle strength, […] The post The Effects of Various Approaches to Lobectomies on Respiratory Muscle Strength, Diaphragm Thickness, and Exercise Capacity in Lung Cancer. first appeared on Physician's Weekly . physiciansweekly - 6h ago - story - | |
| Particle Therapy Market to hit USD 1.7 Bn by 2032, says Global Market Insights Inc. Particle therapy industry is projected to witness a CAGR of 8.8% during the period 2024-2032. This growth can be owing to the increasing number of particle therapy centers worldwide. Particle therapy industry is projected to witness a CAGR of 8.8% during the period 2024-2032. This growth can be owing to the increasing number of particle therapy centers worldwide. globenewswire - 3h ago - story - | |
| Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits DALLAS, April 29, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Samarendra Mohanty, PhD, Co-Founder, and President, will present in the Retinal Cell and Gene... prnewswire:443 - 1h ago - story - | |
| Modi increases anti-Muslim rhetoric in India election campaign PM seeks to mobilise Hindu voters amid signs of low turnout and anti-incumbency sentiment ft - 10h ago - story - | |
| The role of fetal therapy in the management of mirror syndrome: a narrative review. Mirror syndrome (MS) is a condition characterized by the presence of maternal, fetal, and placental edema and is reversible through delivery or pregnancy termination. As fetal hydrops itself may be amenable to treatment, we sought to determine outcomes for MS primarily managed by fetal therapy through a narrative review of the literature and cases managed […] The post The role of fetal therapy in the management of mirror syndrome: a narrative review. first appeared on Physician's Weekly . physiciansweekly - 7h ago - story - | |
| Campus anti-war protesters dig in from New York to California Student anti-war protesters at U.S. college campuses are digging in and vowing to keep their demonstrations going, while some universities have moved to shut down encampments and protests abcnews - 12:14 Sun - story - | |
| Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies - Top-line Results Expected in the Second Half of 2024 - - Top-line Results Expected in the Second Half of 2024 - globenewswire - 42m ago - story - | |
| Higher peripheral blood mitochondrial DNA copy number and relative telomere length in under 48years Indonesian breast cancer patients. Breast cancer is the leading cause of cancer incidence and mortality among Indonesian women. A comprehensive investigation is required to enhance the early detection of this disease. Mitochondrial DNA copy number (mtDNA-CN) and relative telomere length (RTL) have been proposed as potential biomarkers for several cancer risks, as they are linked through oxidative stress mechanisms. […] The post Higher peripheral blood mitochondrial DNA copy number and relative telomere length in under 48years Indonesian breast cancer patients. first appeared on Physician's Weekly . physiciansweekly - 7h ago - story - | |
| How Cancer Research Is Revolutionizing Lyme Disease Treatment Fibroblast growth factor receptor inhibitors, a type of drug previously studied in the context of cancer, shows promise in reducing inflammation and cell death in... scitechdaily - 23:14 Sun - story - | |
| Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer. The cT1a vs. cT1b substratification was introduced in 1992 but never formally tested since. We tested the discriminative ability of cT1a vs. cT1b substaging on cancer-specific survival (CSS) in contemporary incidental prostate cancer (PCa) patients.Incidental (cT1a/cT1b) PCa patients were identified within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015).Kaplan-Meier estimates, as well as uni- […] The post Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer. first appeared on Physician's Weekly . physiciansweekly - 6h ago - story - | |
| 10 Creative Study Tips for Medical Exams Exam preparation for medicine can be extremely difficult and necessitates not only rote memory but also a thorough comprehension of difficult subjects. Because of the large amount of content to cover, using efficient study techniques is crucial to maximizing learning and retention. This article covers ten innovative study strategies designed especially for medical students preparing […] The post 10 Creative Study Tips for Medical Exams appeared first on TechBullion . techbullion - 18:38 Sun - story - | |
| Florida Loses $ 12 Billion Plus In Year 1 Of Its Anti-Immigration Law Why did Florida's anti-immigrant law adopted last year cost so much? There are legal ways for temporary foreign workers to come to Florida. Why aren't they being used? forbes - 1h ago - story - | |
| Can bcbs of Alabama deny breast cancer treatment? My mammogram showed I have a mass inside my right breast on 3/7 via diagnostic mammogram which was covered 100%. My oncology radiologist try to biopsy the mass on3/26 but at that point it wasnt showing on the ultrasound, so he cancelled the biopsy. On 4/23 the breast specialist recommended an mri for diagnostic purposes. They want to make sure that I dont have cancer. Bcbs of Alabama denied the MRI saying it is not medically necessary and even if eventually they do pre authorize they are not covering it, I would have to pay out of pocket. They also said they dont have to follow my state law (I dont live in Alabama). What happens if the state of Alabama changes its laws and decide cancer is not a medical issue but a moral one, like abortion, and insurance companies dont have to pay for cancer treatments? Their laws are already very different than in my state, which mandates yearly mammograms to be covered. Their law only requires mammograms every2 years. Do I have any legal reddit - 09:45 Sun - story - | |
| Forensic neuropsychology Hi, Here are my questions for expert witnesses in neuropsychology (I already asked those questions to neuropsychologists I know, but I want more answers) : 1) Is forensic neuropsychology significantly more stressful than regular clinical neuropsychology? 2) how do lawyers or other clients interact with you? Are they difficult to deal with? 3) Can you do forensic work with 1-2 years of clinical independent experience but with a solid network of consultants? Thats what I plan to do potentially. 4) I know that everyone likes different things, but according to you, why do many neuropsychologists seem not to be interested in the slightest from that field? 5) Do you have resources you recommend me to read on the subject? 6) In Canada or the USA, how much do you personally know someone makes while doing a lot of forensic work, including overheads (lets say 1-2 forensic evaluations per week and one clinical assessment per week)? I know that, contrary to the medical doctors, money seems to reddit - 04:00 Sun - story - |